<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03426748</url>
  </required_header>
  <id_info>
    <org_study_id>H17-02904</org_study_id>
    <nct_id>NCT03426748</nct_id>
  </id_info>
  <brief_title>LDR vs. HDR Brachytherapy for Prostate Cancer</brief_title>
  <acronym>LDR/HDRmono</acronym>
  <official_title>A Phase III Randomized Study of Low Dose Rate Compared to High Dose Rate Prostate Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BC Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>British Columbia Cancer Agency</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      H17-02904 is a randomized comparison of low dose rate vs. high dose rate prostate
      brachytherapy for favorable and intermediate risk prostate cancer suitable for brachytherapy
      as monotherapy. This is a continuation with expanded accrual of the randomized Pilot study
      H15-02103
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Men suitable for prostate brachytherapy as monotherapy will undergo multiparametric Magnetic
      Resonance Imaging for staging and identification of a dominant lesion and will be randomly
      selected for either a single low dose rate permanent seed implant or 2 fractions of high dose
      rate brachytherapy. Using image registration techniques, dominant lesions will be biopsied
      under anesthesia at the start of the brachytherapy procedure. Biopsies will reviewed for
      tumor Gleason score and sent for Cell Cycle Progression testing (Prolaris). Patients
      receiving high dose rate brachytherapy will also have biopsies between the 2 fractions to
      assess tumor changes induced from the first fraction. Post implant quality assurance will
      determine the dose to the dominant lesions and compare these between the 2 types of
      brachytherapy. Post implant symptoms will be tracked for severity and time course.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in Quality of Life in the urinary domain between LDR and HDR brachytherapy.</measure>
    <time_frame>0-36 months</time_frame>
    <description>The urinary domain of the EPIC prostate cancer specific QOL questionnaire will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life in the bowel and sexual domains</measure>
    <time_frame>0-36 months</time_frame>
    <description>The EPIC score in the bowel and sexual domains will be evaluated at baseline, 1, 3, 6, 12, 24 and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to return to baseline +/- 3 points for the International Prostate Symptom Score</measure>
    <time_frame>0-36 months</time_frame>
    <description>The IPS Score will be assessed at baseline, 1, 3, 6, 12, 24 and 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and long term toxicity</measure>
    <time_frame>[Time Frame: 0-10 years]</time_frame>
    <description>Acute and long-term toxicity will be graded using the Common Terminology Criteria for Adverse Events (CTCAE V4) at each follow up time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Outcome</measure>
    <time_frame>5-10 years</time_frame>
    <description>PSA will be recorded every 6 months to 5 years and then annually to 10 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic Outcome</measure>
    <time_frame>3 years</time_frame>
    <description>Prostate re-biopsy will be performed at 36 months to assess the local efficacy of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell cycle progression score</measure>
    <time_frame>1 month to 10 years</time_frame>
    <description>For those patients consenting to targeted biopsies under anesthesia at the start of their brachytherapy procedure (separate optional consent) MRI-TRUS fusion accuracy will be verified by targeted biopsies and Biopsy material will be sent for genetic testing to determine Cell cycle Progression scores for both arms of the trial to ultimately correlate with outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor oxygenation and cell cycle distribution</measure>
    <time_frame>1 month to 10 years.</time_frame>
    <description>For patients receiving 2 fractions of high dose rate brachytherapy, biopsy between the 2 fractions will assess radiosensitivity by evaluating changes in oxygenation and cell cycle distribution between the 2 fractions, for ultimate correlation with efficacy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Low dose rate brachytherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Device: Radiation. Low dose rate prostate brachytherapy is delivered under anesthesia in a single 1.5-2 hour procedure as an out-patient. The men return 4 weeks later for detailed imaging to assess implant quality.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose rate brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: Radiation. High dose rate prostate brachytherapy is delivered in 2 procedures, 2 weeks apart, also under anesthesia, but no follow-up imaging visit is required.
HDR brachytherapy is also accomplished as an out-patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Low dose rate prostate brachytherapy</intervention_name>
    <description>Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance</description>
    <arm_group_label>Low dose rate brachytherapy</arm_group_label>
    <other_name>permanent seed implant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>High dose rate prostate brachytherapy</intervention_name>
    <description>Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate</description>
    <arm_group_label>High dose rate brachytherapy</arm_group_label>
    <other_name>HDR brachytherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Favorable risk and low-tier intermediate-risk prostate cancer with estimated life
        expectancy of at least 10 years.

          -  Clinical stage T1c-T2b, PSA &lt; 20, Gleason &lt; 8

          -  ECOG 0-1

          -  Low tier intermediate-risk prostate cancer is defined by a single NCCN intermediate
             risk factor

          -  Extensive favorable-risk disease is defined as:

               -  clinical stage T1c-T2a

               -  PSA &lt; 10

               -  Gleason 6

               -  ≥ 50% of biopsy cores containing cancer

               -  PSA density &gt; 0.2 ng/cc

          -  Selected intermediate risk patients not defined above

               -  - T1c/T2a

               -  - PSA &lt; 10

               -  -Gleason 4+3

               -  -&lt; 33% of cores involved

               -  -Max tumor length in any core 10 mm

          -  No androgen deprivation therapy (ADT)

          -  Prostate volume by TRUS ≤ 60 cc.

          -  Not eligible for, or accepting of, active surveillance according to NCCN guidelines.

          -  Signed study specific informed consent.

        Exclusion Criteria:

          -  Prior radical surgery for carcinoma of the prostate,

          -  Prior pelvic radiation

          -  Prior chemotherapy for prostate cancer,

          -  Prior TURP or cryosurgery of the prostate

          -  Claustrophobic or unable to undergo MRI
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ross Halperin, MD</last_name>
    <role>Study Director</role>
    <affiliation>British Columbia Cancer Agency Program Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juanita M Crook, MD</last_name>
    <phone>250 712 3958</phone>
    <email>jcrook@bccancer.bc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francois Bachand, MD</last_name>
    <phone>250 712 3900</phone>
    <email>fbachand@bccancer.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>British Columbia Cancer Agency Center for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juanita Crook, MD</last_name>
      <phone>250 712 3958</phone>
      <email>jcrook@bccancer.bc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Francois Bachand, MD</last_name>
      <phone>250 712 3900</phone>
      <email>fbachand@bccancer.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Deidre Batchelar, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Araujo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Petrik, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michelle Hilts, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brenda Farnquist, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Terry Bainbridge, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ross Halperin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Lum, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Crook J, Ots A, Gaztañaga M, Schmid M, Araujo C, Hilts M, Batchelar D, Parker B, Bachand F, Milette MP. Ultrasound-planned high-dose-rate prostate brachytherapy: dose painting to the dominant intraprostatic lesion. Brachytherapy. 2014 Sep-Oct;13(5):433-41. doi: 10.1016/j.brachy.2014.05.006. Epub 2014 Jun 20.</citation>
    <PMID>24958556</PMID>
  </reference>
  <reference>
    <citation>Batchelar D, Gaztañaga M, Schmid M, Araujo C, Bachand F, Crook J. Validation study of ultrasound-based high-dose-rate prostate brachytherapy planning compared with CT-based planning. Brachytherapy. 2014 Jan-Feb;13(1):75-9. doi: 10.1016/j.brachy.2013.08.004. Epub 2013 Sep 27.</citation>
    <PMID>24080299</PMID>
  </reference>
  <reference>
    <citation>Schmid M, Crook JM, Batchelar D, Araujo C, Petrik D, Kim D, Halperin R. A phantom study to assess accuracy of needle identification in real-time planning of ultrasound-guided high-dose-rate prostate implants. Brachytherapy. 2013 Jan-Feb;12(1):56-64. doi: 10.1016/j.brachy.2012.03.002. Epub 2012 Apr 17.</citation>
    <PMID>22513104</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brachytherapy</keyword>
  <keyword>Quality of life</keyword>
  <keyword>High dose rate vs. low dose rate</keyword>
  <keyword>Intermediate risk group</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

